Golden
G1 Therapeutics

G1 Therapeutics

A company developing small molecule therapies to treat cancer

G1 Therapeutics is a publicly traded, clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina that was founded in 2008 by Kwok-Kin Wong and Norman Sharpless. It focuses on the discovery, development, and delivery of therapies that improve the lives of cancer patients. 

Clinical trials

The company is currently running three clinical-stage programs, trilaciclib, lerociclib, and G1T48. They are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications. Trilaciclib and lerociclib are CDK4/6 indicators, which have broad therapeutical potential in many forms of cancer. G1T48 on the other hand is a oral selective estrogen receptor degrader (SERD), which is targeted for the treatment of ER+ breast cancer.

Trilaciclib

Trilaciclib is a first-in-class myelopreservation therapy that is designed to improve outcomes of patients who receive chemotherapy by preserving hematopoietic stem and progenitor cell (HSPC) and immune system functions. It is a short-acting intravenous CDK4/6 administered prior to chemotherapy. Trilaciclib is being evaluated in four randomized Phase 2 trials. In December 2018, G1 announced positive topline results from these trials.

Lerociclib

Lerociclib is a potential oral CDK4/6 inhibitor that is being developed for use in combination with other targeted therapies in multiple oncology indications. The product is being evaluated in two Phase 1/2 clinical trials, a trial in combination with Faslodex for patients with estrogen receptor positive, HER2-negative (ER+, HER2-) breast cancer and a trial in combination with Tagrisso in EGFRm non-small cell lung cancer. The latter trial is a clinical trial collaboration with AstraZeneca.

G1T48

G1T48 is an oral selective estrogen receptor degreader (SERD). G1 has initiated a Phase 1/2a clinical trial of G1T48 in estrogen-receptor positive, HER2-negative (ER+, HER2-) breast cancer. The company is also planning to combine lerociclib and G1T48 as a potential all-oral regiment in this indication.

Partnerships

AstraZeneca

In 2017, G1 also entered into a clinical trial collaboration with AstraZeneca to evaluate the latter company's epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

Funding

Venture

On October 12, 2012 G1 Therapeutics completed a venture funding round with $762,900 in funding from undisclosed investors. 

Series A

On October 16, 2013 G1 Therapeutics completed their series A funding round with $12.5 million in funding from MedImmune Ventures (lead investor), Mountain Group Capital, and Hatteras Venture Partners. 

Series B

On February 5, 2015 G1 Therapeutics completed their series B funding round with $33 million in funding from Ra Capital Management (lead investor), Eshelman Ventures (lead investor), Mountain Group Capital, MedImmune Ventures, Lumira Ventures, and Hatteras Venture Partners. 

Series C

On May 11, 2016 G1 Therapeutics completed their series C funding round with $47 million in funding from Cormorant Asset Management (lead investor), Tavistock Life Sciences, Rock Springs Capital, RA Capital Management, Mountain Group Capital, MedImmune Ventures, Lumira Ventures, Hatteras Venture Partners, Franklin Templeton Investments, Eshelman Ventures, and Cowen Group. 

Timeline

March 29, 2019

Series B funding round

On February 5, 2015 G1 Therapeutics completed their series B funding round with $33 million in funding from Ra Capital Management (lead investor), Eshelman Ventures (lead investor), Mountain Group Capital, MedImmune Ventures, Lumira Ventures, and Hatteras Venture Partners. 

March 29, 2019

Series C funding round

On May 11, 2016 G1 Therapeutics completed their series C funding round with $47 million in funding from Cormorant Asset Management (lead investor), Tavistock Life Sciences, Rock Springs Capital, RA Capital Management, Mountain Group Capital, MedImmune Ventures, Lumira Ventures, Hatteras Venture Partners, Franklin Templeton Investments, Eshelman Ventures, and Cowen Group. 

October 16, 2013

Series A funding round

On October 16, 2013 G1 Therapeutics completed their series A funding round with $12.5 million in funding from MedImmune Ventures (lead investor), Mountain Group Capital, and Hatteras Venture Partners. 

October 12, 2012

Venture funding round

On October 12, 2012 G1 Therapeutics completed a venture funding round with $762,900 in funding from undisclosed investors. 

Funding rounds

1 Result
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Barclay A. "Buck" Phillips

CFO & Senior VP, Corporate Development



James Stillman Hanson

General Counsel



Jay Strum

Chief Scientific Officer



John Demaree

Chief Commercial Officer



Joseph Nixon

Investor



Mark Velleca

CEO



Rai Malik

Chief Medical Officer & Senior VP, R&D



Terry Murdock

COO



Further reading

Title
Author
Link
Type
Date

G1 Therapeutics & AstraZeneca Enter Clinical Trial Collaboration

G1 Therapeutics

Web



G1 Therapeutics reports more promising results for cancer drug | WRAL TechWire

Bryant Haskins

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References